Table 3.
Assessment of Treatment Response in the Patients Receiving Additional TTT after IVB as Primary Treatment for Subfoveal Fluid
| No. | Age range / Sex | 1st Tx. #No. | SFF 1st Response | 2nd Tx. #No. | SFF 2nd Response | Additional therapy | Pre IVB SFF height (μm) | Post IVB, pre TTT SFF height (μm) | Post TTT SFF height (μm) | Tumor growth |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 40–50/F | IVB#3 | None | TTT #2 | Complete | 114 | 167 | 0 | ↑ | |
| 11 | 70–80/F | IVB#1 | None | TTT #3 | Partial | Brachy Tx. | 380 | 390 | 54 | ↑ |
| 13 | 40–50/F | IVB#2 | None | TTT #3 | Partial | Brachy Tx. | 292 | 671 | 315 | ↑ |
| 14 | 40–50/M | IVB#3 | Partial | TTT #2 | Complete | 265 | 116 | 0 | → | |
| 12 | 40–50/F | (1) IVB#1 (3) IVB#2 (5) IVB#2 |
None | (2) TTT #2 (4) TTT #1 |
None | Brachy Tx. | ↑ |
IVB intravitreal bevacizumab injection, TTT transpupillary thermotherapy, No. number, Tx. Therapy, 1st primary, 2nd secondary, SFF subfoveal fluid, M male, F female